北京招聘

Primary Function:

Undertake day-to-day operations within the Pharmacology Discipline under the direction of Team Leader. Be an instrumental member of a team engaged in testing agents in pre-clinical in vitro and in vivo models of cancer and autoimmune disease.

Major Responsibilities and Duties:

1) Tissue culture and PD sample analysis with Western blot, ELISA, FACS.

2) Undertake daily lab operation work within the discipline as required.

3) Work with external partners and CROs to conduct the study

4) The experiment design delivery of high quality in vitro and in vivo data as agreed with the team leader or project supervisor

5) Providing expert interpretation of the data, identifying innovative solutions to problems and putting forward plans for further experiments

6) Communicating data and key findings in a clear and concise manner, demonstrating a good understanding of its implications within the overall context of the project

7) Organize, report and communicate study outcome to the project team.

8) Maintain clear records of experimental work.

9) Perform multi-tasks and participate in several projects simultaneously.

10) Work closely with scientists from other divisions, such as antibody discovery, biology groups, etc

Qualifications:

1) PHD in immunology or pharmacology with a minimum of 1 year's hands-on experience working with in vitro molecular, cell biology and pharmacology-related techniques which are relevant to cancer research, target validation and compound profiling such as growth inhibition and cytotoxicity assays, western blotting, cell cycle analysis and flow cytometry, and immunofluorescence imaging

2) Good English skills both in oral and written.

3) Passion for research with can-do attitude and problem-solving skills

4) Good communication skills and an ability to work independently within a team and in a project-oriented environment are essential

Zai Lab is an innovative biopharmaceutical company based in Zhang Jiang, Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab focus on innovation to meets the unmet medical needs. Zai has built up a strong pipeline with multiple programs on clinical stages. Zai Lab successfully listed on Nasdaq in Sep. 2017.

再鼎医药是一家总部设立于上海张江，致力于研究、开发和销售创新药物的制药企业。再鼎医药针对目前尚无良好治疗手段的疾病领域开发新药，在肿瘤、抗感染、自身免疫等方面建立了全面的产品线，服务中国和全球病患。再鼎医药于2017年9月在美国纳斯达克成功上市。